Department Publications (35)

Body A, Ahern E,  Segelov E.  COVID-19 vaccinations for patients with cancer- many remain unvaccinated despite having priority in the vaccine rollout. IMJ https://doi.org/10.1111/imj.15497

Grønlie Guren M, Sebag-Montefiore D, Franco P, Johnsson A, Segelov E  , Deutsch E, Rao S, Garm Spindler KL, Arnold D. 2021. Treatment of squamous cell carcinoma of the anus, unresolved areas and future perspectives for research. Clinical Colorectal Cancer. 2021 Sep 15

Suie H, Tebbutt N, Chantrill L, Karapetis C, Steer C, Wilson K, Espinoza D, Bailey L, Yip S, Cuff J, Pavlakis N, Thavaneswaran S, Briscoe K, Srivastav R, Shannon J,  Segelov E  , Tie J, Caird S,  Francesconi A, Price T, Wuttke M, Ladwa R, Sjoquist K, Burge M. 2021 MONARCC: A randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer vol. 21, issue 1.

Elston M, Love A, Kevat D, Carroll R, Siow Z, Pattison S, Segelov E, Wyld D, Strickland A, Ransom D. 2021. Hypopituitarism following peptide receptor radionuclide therapy for neuroendocrine tumours. Int J Cancer online 26 Oct  DOI: 10.1002/cam4.4345

Masoumi-Moghaddam S, Lundy J, Gao H, Rathi V, Swan M, Desmond C, Bhutani MS, Southey MC, Vaughan R, Varma P, Tagkalidis P, Holt BA, C Pilgrim CH,  Segelov E,  , Lee B, Harris M, Strickland A, Frentzas S, Zalcberg J, Jenkins B, Croagh D. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Endosc Ultrasound. 2021 Sep 23. doi: 10.4103/EUS-D-20-00230. Epub ahead of print. PMID: 34558422.

Body A, Latham S, Kong JB, Raghunath A, Segelov E. Stage III colon cancer: is neoadjuvant chemotherapy ready for prime time? A narrative review of neoadjuvant chemotherapy for colon cancer. Dig Med Res 2021.

Segelov E, Carrington C, Aranda, S.K., Currow, D., Zalcberg, J., Heriot, A.G., Mileshkin, L., Bashford, J., Coutsouvelis, J., O’Kane, C. and Sulkowsk, A., Wale, J., Hancock, S., Bichel-Findlay, J., Millar, J., Emery, J., Zhang, P., Collopy, B., & Cooper, S. 2021. Developing clinical indicators for Oncology: the inaugural indicator set for the Australian Council on Healthcare Standards Med J Aust 30 May 2021

Body A, Tipping-Smith S, Lam M, Prenen H, Segelov E. 2021. The role of neoadjuvant therapy in locally advanced colon cancer. Cancer Management and Research. 13:2567-2579

Kwan E, Fettke H, Docanto M, To S, Bukczynska P, Mant M, Pook D, Ng N, Graham LJ, Mangiola S, Segelov E, Mahon K, Davis I, Parente P, Pezaro C, Todenhofer T, Sathianathen S, Hauser C, Horvath L, Azad A. 2021.Prognostic utility of a Whole blood androgen-receptor based gene signature in metastatic castrate-resistant prostate cancer. European Urology Focus. 7:1:63-70.

Vignoli A, Risi E, McCartney A, Migliaccio I, Moretti E, Malorni L, Luchinat C, Biganzoli L, Tenori L. Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. Int J Mol Sci. 2021 Apr 28;22(9):4687. doi: 10.3390/ijms22094687. PMID: 33925233.

Ahern, E., Solomon, B.J., Hui, R., Pavlakis, N., O’Byrne, K., & Hughes, B.G.M. (2021). Neoadjuvant immunotherapy for non-small cell lung cancer: Right drugs, right patient, right time? J Immuno Ther Cancer, in press.

Rao, S., Tu, W.J., McCuaig, R., Melino, M., Rawle, D., Le, T., Yan, K., Suhrbier, A., Johnston, R., Koufariotis, L., Waddell, N., Cross, E., Tsimbalyuk, S., Bain, A., Ahern, E., Collinson, N.,  Phipps, S., Forwood, J., & Seddiki, N. (2021). Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell Discov, in press.

Gasper, H., Ahern, E., Roberts, N., Chan, B., Hughes, B.G.M., Kennedy, G., Wyld, D., Eastgate, M., & Lwin, Z. (2021). A semi-qualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID 19 preparations in South-East Queensland, Australia. Br J Cancer (Open), in press.

Ives, A., Pusztai, T., Keller, J, Ahern, E., et al. (2021). Resilience and ongoing quality care for cancer clinical trials during Covid-19: experience from a tertiary hospital in Australia. Asia Pac J Clin Oncol. doi: 10.1111/ajco13570

M.Ali, H.Kua, C.Giddings, D.Day, L.McDowell, Synchronous p16+ Nasopharyngeal and Oropharyngeal Squamous Cell Carcinoma: A Case Report and review. Authorea Sept 2020. http://doi.org/10.22541/au.159986304.46627658. (Co.author)

S.David, G. Ho, D.Day, M.Harris, R.Srivastava, M.White. Enhanced toxicity with CDK 4/6 inhibitors and pallitive radiotherapy: Non-consecutive case series and review of the literature. Transl Oncol. 2021 Jan:14(1):100939. doi: 10.1016/j.tranon.2020.100939. Epub 2020 Nov 20. (Co-author)

Davies A, Lum C, Ragu R, Ansell E, Webber K, Segelov E. 2021. Anti-cancer therapy made easier: a 25-year update. Int Med J. 51 473-480

Hanna C, Robles-Zurita J, Briggs A, Harkin A, Kelly C, Allan K, McQueen, Pearson S, Hollander N, Glimelius B, Salazar R, Segelov E, Saunders M, Iveson T, Jones J, Boyd K. 2021. Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: multi-country cost effectiveness and budget impact analysis. Clinical Colorectal Cancer. 2021 Apr 15

Muhandiramge J, Vu T, Wallace M, Segelov E. 2021. The experiences, attitudes and understanding of research amongst medical students at an Australian medical school. BMC Medical Education. 21:267

Detailleur S, Del Re M, Prenen H, Segelov E. 2021 Dihydropyrimide dehyrogenase deifiency in patients with seere toxicity after 5-fluorouracil: a retrospective single center study. Annals of Gastroenterology. 2021;34(1):68

Jackson C, Hung T, Segelov E, Barlow P, Prenen H, Mclaren B, Hung N, Clarke K, Chao T, Dai M, Yeh H, Cultler D, Kramer D, He J, Zhi J, Chan W, Kwan R, Deva S. 2021. Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: a randomised crossover pharmacokinetic study. British Journal of Clinical Pharmacology 2021-1-11.

Biganzoli L, Battisti NML, Wildier H, McCartney A, Colloca G, Kunkler IH, Caroso MJ, Cheung KL, de Glas NA, Trimboli RM, Korc-Grodzicki B, Soto-Perez-de-Celis E, Ponti A, Tsang J, Marotti L, Benn K, Aapro MS, Brain EGC. updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). Lancet Oncol. 2021 May 14: S1470-2045(20)30741-5. doi: 10.1016/S1470-2045 (20)30741-5. Epub ahead of print.

Galardi F, De Luca F, Biangioni C, Migliaccio I, Curigliano G, Minisini AM, Bonechi M, Moretti E, Rise E, McCartney A, Benelli M,Romagnoli D, Cappadona S, Gabellini S, Guarducci C, Conti V, Biganzoli L, Di Leo A, Malorni L. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021 Mar 24;23(1):38.

Migliaccio I, Bonechi M, McCartney A, Guarducci C, Benelli M, Biganzoli L, Di Leo A, Malorni L. CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer. Cancer Treat Rev. 2021 Feb;93:102136.

Kwan E, Fettke H, Crumbaker M, Docanto M, To S, Bukczynska P, Mant M, Ng N, Foroughi S, Graham L-J, Haynes A-M, Azer S, Lim, Segelov E, Mahon K, Davis I, Parente P, Pezaro C, Todenhofer T, Sathianathen S, Hauser C, Horvath L, Joshua A, Azad A. 2021. Whole blood GRHL2 expression as a prognostic biomarker in metastatic prostate cancer. Translational Andrology and Urology. 10.4 (2021):1688

Davies A, Foo M, Gan CL, Kouranbas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, Segelov E, Bradley J, Soo  G, Ramdave S, Kwan E, Azad A. 2021 Ga-prostate  specific membrane antigen (PSMA) PET_CT as a clinical decision-making tool in biochemically recurrent prostate cancer, AJPCO. 2021:1-7

Kanajapan Y, Blinman P, Underhill C, Karikios D,  Segelov E ,  Yip D. Medical Oncology Group of Australia Position Statement: COVID-19 vaccination in patients with solid tumours 2021. IMJ. 51:6:955-959.

68-Ga-prostate specific membrane antigen (PSMA) PET_CT as a clinical decision-making tool in biochemically recurrent prostate cancer, AJPCO. Asia-Pac Clini Oncol 2021:1-7.

Menon S, Davies A, Frentzas S, Hawkins C, Segelov. E, Day D, Markman B. 2021 Recruitment, outcomes and toxicity trends in phase 1 oncology trials: six year experience in a large institution Cancer reports. 10 July 2021

Wen Juan Tu, Robert D. McCuaig, Michelle Melino, Daniel J. Rawle, Thuy T. Le, Kexin Yan, Andreas Suhrier, Rebecca L. johnson, lambros T. Koufariotis, Nicola Waddell, Emily M. Cross, Sofiya Tsimbalyuk, Amanda Bain, Elizabeth Ahern, Natasha Collinson, Simon Phipps, Jade K.Forwood, nabila Seddiki, Sudha Rao, Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication. Cell discovery. 2021 May 24;7(1): 1-25.

Ives A, Pusztai T, Keller J, Ahern E, Chan B, Gasper H, et al. Resilience and ongoing quality care for cancer clinical trials during COVID-19: experience from a tertiary hospital in Australia. Asia-Pac J Clin Oncol. 2021;1-7.

Gasper, H., Ahern E, Roberts, N., Chan, B., Hughes, B., Kennedy, G., Wyld, D., Eastgate, M., and Lwin, Z., 21. Seminqualitative research protocol to explore cancer care workforce perceptions of the health system response to COVID-19 preparations in Southeast Queensland, Australia.BMJ open, 11(5), p.e044655.

Balasubramanian A, Qu L, Weickhardt A, Bolton D, Perera M. Changes in prescribing habits for the treatment of metastatic renal clear cell carcinoma (mRCC) in Australia. Intern Med J. 2021 Jul;51(7):1173-1177.

Meessen S, Currey N, Jahan Z, Parker H, Segelov E, Dahlstrom J, Kohonen-Corish M. 2021. MSH-3 tetranucleotide repeat instability is inversely associated with the CpG island methylator phenotype Cancers. 13(14), 3529.

Davies A, Garvey G, Diaz A, Gurney J, Segelov E​. Cancer care disparities among Australian and New Zealand First Nation Peoples. 2021. Current Opinion in Supportive & Palliative Care. July 7 2021.

Sweeney, C. J., Martin, A. J., Stockler, M. R., Begbie, S, Chi, K. N., Chowdhury, S, Pook D. & Davis, I. D. (2021). Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology.2021 May 22.

Elizabeth Ahern, Ben J Solomon, Rina Hui, Nick Pavlakis, Ken O’Byrne, Brett G M Hughes. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time. J Immunother Cancer: 9(6):e003348.

 

Abstracts (25)

Liow E, McLaren C, Smith S, Latham S, Kong J, Lam M, Lum C, Body A, Briggs P, Segelov E. 2021. Systemic anticancer treatment changes at the start of the COVID-19 pandemic in a large metropolitan health service. Clin Cancer Res March 15 2021 (27) (6 Supplement) P19

Hurvitz S, Park H, Frentzas S, Shannon V, Cuff K, Eek R, Budd GT, McCartney A, O’Shaughnessy J, Lu L, Zhang J, Wang L, Li M, Yan J, Xia G, Ji Y, Xiong G, Yai S, Liang X, Hu X. Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: results from two Phase 1 clinical trials.

Malorni L, Romagnoli D, Benelli M, Galardi F, Biagioni C, Curigliano G, Minisini AM, Moretti E, Risi E, De Luca F, McCartney A, Di Leo A, Biganzoli L, Migliaccio I. Mutational analysis of circulating tumor DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): results from the TREnd trial. Annals of Oncology. 2021 May 1;32:S24

Lam M, Delaney J, Segelov E: Improving Telehealth Accessibilty During the COVID-19 Pandemic in an Australian Oncology Outpatient Service Oral Presentation Medical Oncology group of Australia ASM 2021 (virtual)

J.Goh, J.Coward, B.Gao, I> da Silva, M.Voskoboynik, D.Day, A.L. Body, H.K.. Gan, C.Chen, X.Xiang, C.Fei, L.ynag, M.Millward. Safety/tolerability and preliminary antitumor activity of sitravatanib plus tislelizumab in patients with advanced platinum-resistant ovaruan cancer (PROC). Presented at: AACR Annual Meeting 2021: April 10-15, 2021; virtual. Abstract CT013.

D.Day, J.W.K.Chia, E.M.J.Foo, R.Ali, H.C.Toh, E.Segelov. Operational challenges of an Asian Pacific (APAC) academic oncology clinical trial. Annuls of Oncology. Vol 31, Supp 6, S1280. Nov 01 2020.

B. Markman, D.Day, H.Gurney, j.Coward, S.Bishnoi, D.Kotasek, R.Eek, M.Brown, C.Lemech, J.Kuo, A.Prawira, R.Strother, Q.Zhang, L.Wang, R.Cheng, Y.Ma, Z.Qin, A.Tsw. Prelimininary pharmacokinetics (PK) safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours:200 mg every 3-weeks (Q3W) and 400 mg every 6-week (Q^W) dosing. Annals of Oncology. Vol 31, Supp 4, S722, Sep 01 2020.

Muhandiramge J, Vu T, Wallace M,. Segelov E. Building the next generation of clinicaian scientist: the experiences, attitudes and understanding of research amongst Australianmedical students. Asia Pacific medical Education Conference (APMEC) 2021, Singapore/virtual 10.13140/RG.2.15032.98567

Ho GY, Wu J, Barker H, Nguyen-Dumont T, Change J, Eggenhuizen P, Stein J, Manolitsas T, Fretzas S, bedo J, Vandenberg C, Papenfuss T, Scott C, Segelov E, Ooi J. Whole  genome and exome sequencing of a rare ovarian carcinosarcoma identify tumour neoantigens that are targetable with CD8+ T cytotoxic cells. Lorne Cancer Conference, Victoria, Feb 2021

Webber K, Cook O, Kwok A, White M, Segelov E. The impact of COVID-19 on the collection of PROMs in an outpatient oncology clinic: from the wating room to telehealth. COSA PMS down Under conference April 2021, virtual.

Frentzas, Sophia. Tarek Meniawy, Steven Chuan-Hao Kao, Ruihua Wang, Yunxia Zuo, Hao Zheng, and Wei Tan. “AdvanTIG-105. Phase 1 dose escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tisleizumab in patients with advanced solid tumors.” (2021): 2583-2583.

Coward, Jermaine, Anna Rachelle Austria Mislang, Sophia Frentzas, Charlotte Rose Lemech, Adnan Nagrial, Xianoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek and Yu Xia. “Safety and efficiency of Ak112, an anti-PD-1/VEGF-A bispecific antibody. In patients with advanced soldi tumors in a phase 1 dose escalation study.”(2021): 2515-2515.

Markman, Ben, AmyHsin-Chein Hsieh, Jermaine Coward, Matteo S, Carlino , Sophia Frenzas, Xiaoping Jin, Baiyong Li, Zhongmin Maxwell Wang, Kon Yew Kwek, and Yu Xia. “A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastic soldi tumors.” (2021): TPS2675-TPS2675.

Frentzas, S., Kwek, K.Y., Konpa,A and Jin, X. 2021 P48, 17 Efficacy and Safety of AK104, and Anti PD-1/CTLA-4 Bispecific Antibody, in a Patient with Large Cell Neuroendocrine Carcinoma of the Lung. Journal of Thoracic Oncology, 16(3), p.S506.

Davies, A., S.Menon, and M.Alamgeer. “P01.22 Outcomes in NSCLC Patients with Early Terimination of Immune Checkpoint Inhibitors Due to Toxicities.” Journal of Thoracic Oncology 16, no.3 (2021): S245

Hurvitz S, Park H, Frentzas S, Shannon C, Cuff K, Eek R, Budd GT, McCartney A, O’Shaughnessy J, Lu L, Zhang J, Wang L, Li M, Yan J, Xia G, Ji Y, Xiong G, Yao S, Liang X, Hu X. Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: results from two Phase 1 clinical trials. JCO 2021: 1038-1038.

Malorni L, Romagnoli D, Benelli M, Galardi F, Biagioni C, Curigliano G, Minisini AM, Moretti E, Risi E, De Luca F, McCartney A, Di Leo A, Biganzoli L, Migliaccio I. Mutational analysis of circulating tumor DNA (ctDNA) in patients with ER+/HER2- advanced breast cancer (ABC) receiving palbociclib (P): results from the TREnd trial. Ann Oncol May 2021 32:S24

Malorni L, Tyekucheva S, Hilbers F, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux F, MacPherson I, Thomson A, Davies DM, Bergqvist M, Benelli M, McCartney A, De Swert H, Ruepp B, Rabaglio M, Maibach R, Piccart M, Regan MM. Serum thymidine kinase activity in patients with luminal metastatic breast cancer treated with palbociclib and fulvestrant within the PYTHIA trial. Cancer Res 2021 81 (4 Supplement) PS5-05-

Sara A. Hurvitz, Haeseong Park, Sophia Frentzas, Catherine M. Shannon, Katharine Cuff, Richard Wilhelm Eek, George Thomas Budd, Amelia McCartney, Joyce O’Shaughnessy, Janice M. Lu, Jian Zhang, Dongmei Ji, Weina Shen, Matt Li, Jinchun Yan, Gang Xia, Yanping Ji, Sulan Yao, Gaozhun Xiong, and Xichun Hu. Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials. Journal of Clinical Oncology 2021 39:15_suppl, 1038-1038.

Understanding the associations of chemotherapy with sleep disturbance and sleep quality in lung cancer patients: A systematic review”  Jeklin, AT , Kumarahuru,  . , Alamgeer  , M. , Stirling, R. , Maccora, J.  , Paul, D.  & Wiley J. Accepted for ESMO 2021

Di Donato S, Vignoli A, Biagioni C, Malorni L, Mori E, Tenori L, Calamai V, Parnofiello A, Di Pierro G, Migliaccio I, Cantafio S, Baraghini M, Mottino G, Becheri D, Del Monte F, Miceli E, McCartney A, Di Leo A, Luchinat C, Biganzoli L. A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting. Cancers 2021; 13(11): 2762 https://doi.org/10.3390/cancers13112762​

Book Chapters and Books

Balasubramanian A, John A, Segelov E. Current state of chemotherapy and immunotherapy regimens in gastric cancer. Invited chapter in Research and Clinical Applications of Targeting Gastric Neoplasms. Academic Press, 2021. 289-316.

Caroline Lum, Sophia Frentzas. Clinical Applications of targeting Gastric Neoplasms: Case Studies Highlighting The Mulitple facets of Gastric Cancer: One diagnosis, Multiple Approaches . Invited chapter in Research and Clinical Applications of Targetin Gastric Neoplasms. Academic Press, 2021. 317-342.

 

 

Book your COVID-19 vaccination -Find out more
+